AstraZeneca, Daiichi Sankyo unveil Phase 3 results for TROP2-directed ADC
The first Phase 3 results for AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody drug conjugate showed a statistically significant…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Jul 23
The first Phase 3 results for AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody drug conjugate showed a statistically significant…
28 Jun 23
The US FDA granted Fast Track designation to NgG, since gonorrhoea is recognised as an urgent unmet medical…
28 Jun 23
The once-daily fixed-dose combination has been approved for type-2 diabetes by the NMPA as an adjunct to diet…
28 Jun 23
The approval of the IgG4 monoclonal antibody is for adult patients suffering from the rare long-term autoimmune disorder…
28 Jun 23
Submissions based on positive Phase 3 data from BENEGENE-2 trial
27 Jun 23
Camzyos is an allosteric and reversible inhibitor that works by modulating the number of myosin heads that can…
23 Jun 23
Elevidys (delandistrogene moxeparvovec-rokl) is an adeno-associated virus (AAV)-based gene therapy indicated for the treatment of ambulatory paediatric patients,…
22 Jun 23
Blincyto is a bispecific T-cell engager (BiTE) immuno-oncology therapy that targets CD19 surface antigens on B cells, to…
20 Jun 23
CART-ddBCMA is a BCMA-specific CAR-modified T-cell therapy that uses the company’s BCMA-targeting binding domain for the treatment of…
19 Jun 23
Columvi (glofitamab-gxbm) is a CD20xCD3 T-cell-engaging bispecific antibody designed to target CD3 on the surface of T-cells and…